Signature Formulations' CBD Products Meet FDA Drug Policy On Claims, GMPs
This article is powered by The Rose Sheet
Executive Summary
FDA's warning letter to Phoenix firm lists violations of the agency's GMP regulations for drug products found in an October-November 2017 inspections in addition to identifying violative claims for its balms, creams, gels, oils, salves and toothpastes containing CBD and other botanicals.